

# Global Sedation Drugs and Companies Pipeline Review H2 2016

*Sedation Therapeutic Pipeline Market Review, H2 2016*

PUNE, INDIA, September 1, 2016 /EINPresswire.com/ --  
Summary

'[Sedation](#) - Pipeline Review, H2 2016', provides an overview of the Sedation pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Sedation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sedation and features dormant and discontinued projects.



WISE GUY RESEARCH  
CONSULTANTS PVT LTD

Complete report details @ <https://www.wiseguyreports.com/reports/619268-sedation-pipeline-review-h2-2016>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Request a sample report @ <https://www.wiseguyreports.com/sample-request/619268-sedation-pipeline-review-h2-2016>

## Scope

- The report provides a snapshot of the global therapeutic landscape of Sedation

- The report reviews pipeline therapeutics for Sedation by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Sedation therapeutics and enlists all their major and minor projects
- The report assesses Sedation therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Sedation

#### Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Sedation
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Sedation pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @ <https://www.wiseguyreports.com/enquiry/619268-sedation-pipeline-review-h2-2016>

Key points in table of content

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Sedation Overview 7

Therapeutics Development 8

Pipeline Products for Sedation - Overview 8

Sedation - Therapeutics under Development by Companies	9
Sedation - Pipeline Products Glance	10
Late Stage Products	10
Clinical Stage Products	11
Early Stage Products	12
Sedation - Products under Development by Companies	13
Sedation - Companies Involved in Therapeutics Development	14
AstraZeneca Plc	14
Drawbridge Pharmaceuticals Pty Ltd	15
Jiangsu Nhwa Pharmaceutical Corporation Ltd.	16
NanoMedex Pharmaceuticals, Inc.	17
Paion AG	18
Primex Pharmaceuticals Oy	19
The Medicines Company	20
Therakind Limited	21
Sedation - Therapeutics Assessment	22
Assessment by Monotherapy Products	22
Assessment by Target	23
Assessment by Mechanism of Action	25
Assessment by Route of Administration	27
Assessment by Molecule Type	29
Drug Profiles	30
ABP-700 - Drug Profile	30
Product Description	30
Mechanism Of Action	30
R&D Progress	30
ADV-6209 - Drug Profile	32
Product Description	32
Mechanism Of Action	32
R&D Progress	32
alphaxalone - Drug Profile	33
Product Description	33
Mechanism Of Action	33
R&D Progress	33
clonidine hydrochloride - Drug Profile	35
Product Description	35
Mechanism Of Action	35
R&D Progress	35
EL-001 - Drug Profile	36
Product Description	36
Mechanism Of Action	36
R&D Progress	36
propofol - Drug Profile	37

Product Description 37  
Mechanism Of Action 37  
R&D Progress 37  
propofol microemulsion - Drug Profile 38  
Product Description 38  
Mechanism Of Action 38  
R&D Progress 38  
remimazolam - Drug Profile 39  
Product Description 39  
Mechanism Of Action 39  
R&D Progress 39  
Small Molecule to Agonize GABA-A for Sedation - Drug Profile 45  
Product Description 45  
Mechanism Of Action 45  
R&D Progress 45  
Sedation - Dormant Projects 46  
Sedation - Discontinued Products 47  
Sedation - Product Development Milestones 48  
Featured News & Press Releases 48  
Jun 19, 2016: Paion Reports Positive Remimazolam Headline Data In Pivotal U.S. Phase III Study  
In Procedural Sedation For Colonoscopy 48  
Apr 11, 2016: Paion Successfully Completes Patient Recruitment In Phase III Study With  
Remimazolam For Procedural Sedation During Colonoscopy 49

Buy this report @ [https://www.wiseguyreports.com/checkout?currency=one\\_user-USD&report\\_id=619268](https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=619268)

Norah Trent  
wiseguyreports  
+1 646 845 9349 / +44 208 133 9349  
[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/342711492>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.